已为您找到该学者16条结果 成果回收站
黎明涛, Wenya Wang a, Leyu Shi a, b, Yuanbin Xie b, Chi Mab, Wenming Li c, Xingwen Su a, Shoujian Huang a, Ruzhu Chen a, Zhenyu Zhu b, Zixu Mao d, Yifan Han c, Mingtao Li a, *
Neuroscience Research 48 (2004) 195~202,-0001,():
-1年11月30日
Increasing evidence suggests that c-Jun N-terminal kinase (JNK) is an important kinase mediating neuronal apoptosis in Parkinson's disease (PD) model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In order to study roles of JNK activity in neuronal apoptosis in this model, we blocked JNK activity in vivo using a specific inhibitor of JNK, SP600125. Our data showed that MPTP-induced phospho-c-Jun of substantial nigral neurons, caused apoptosis of dopaminergic neurons, and decreased the dopamine level in striatal area. We found that inhibiting JNK with SP600125 reduced the levels of c-Jun phosphorylation, protected dopaminergic neurons from apoptosis, and partly restored the level of dopamine in MPTP-induced PD in C57BL/6N mice. These results indicate that JNK pathway is the major mediator of the neurotoxic effects of MPTP in vivo and inhibiting JNK activity may represent a new and effective strategy to treat PD.
1-Methyl-4-phenyl-1,, 2,, 3,, 6-tetrahydropyridine, SP600125, c-Jun N-terminal kinase, Phospho-c-Jun, Dopaminergic neurons, Parkinson, Mouse
-
110浏览
-
0点赞
-
0收藏
-
0分享
-
254下载
-
0
-
引用
黎明涛
,-0001,():
-1年11月30日
-
76浏览
-
0点赞
-
0收藏
-
0分享
-
120下载
-
0
-
引用
黎明涛, Hong-Wei Yang, , Xiao-Dong Hu, Hong-Mei Zhang, Wen-Jun Xin, Ming-Tao Li, Tong Zhang, Li-Jun Zhou, and Xian-Guo Liu
J Neurophysiol 91: 1122~1133, 2004.,-0001,():
-1年11月30日
-
64浏览
-
0点赞
-
0收藏
-
0分享
-
46下载
-
0
-
引用
黎明涛, Xuemin Wang‡§, Xiaoli Tang‡§, Mingtao Li¶, John Marshall, and Zixu Mao‡**
Vol. 280, No.17, Issue of April 29, pp. 16705~16713, 2005,-0001,():
-1年11月30日
The transcription factor myocyte-enhancer factor 2 (MEF2) has been shown to be required for the survival of different types of neurons. However, the death- or survival-inducing second messenger pathways that regulate MEF2 activity remain to be fully elucidated. Membrane depolarization by KCl induces neuronal survival that is dependent upon MEF2-mediated gene transactivation. Here we report that membrane depolarizationinduced activation of MEF2 requires the cAMP-protein kinase A (PKA) pathway. Inhibition of the activity of cAMP-PKA pathway attenuates membrane depolarization-induced activation of MEF2 activity and neuronal survival, whereas enhancing the activity of this pathway prevents KCl withdrawal-induced inhibition of MEF2 and neuronal apoptosis. Moreover, PKA directly phosphorylates MEF2 at Thr-20 in vitro to increase MEF2 DNA binding activity. A mutation of Thr-20 to Ala renders MEF2 resistant to PKA phosphorylation in vitro and reduces its DNA binding activity. Transfection of this T20A mutant blocks survival and induces apoptosis in cultured cortical and cerebellar granule neurons. This study identifies the transcription factor MEF2 as a target of cAMP-PKA pathway and demonstrates that PKA phosphorylation of MEF2 is a key step in modulating its DNA binding activity and ability to promote neuronal survival.
-
79浏览
-
0点赞
-
0收藏
-
0分享
-
122下载
-
0
-
引用
黎明涛, by Wenya Wang, Chi Ms, Zixa Mao and Mingtao Li
,-0001,():
-1年11月30日
Parkinson's disease is characterized by the pathologicalloss of dopaminergic neurons in the substantia nigra. The current therapy for Parkinson's disease is aimed to replace the lost transmitter. But the ultimate objective in the neurodegenerative therapy is the functional restoration and/or cessation of progression of neuronal loss. Given the critical role that the c-Jun N-terminal kinase (JNK) pathway plays in regulating the cellular processes that are involved in Parkinson's disease, the importance of JNK in this disease's pathogenesis is being increasingly recognized. Much evidence suggests that JNK plays an important role in mediating 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridnium ion (MPP+)-induced neurotoxicity. Therefore, direct blockade of JNK may prevent or effectively slow the progression of Parkinson's disease. Studies including our own showed that the inhibition of JNK with SP-600125, a specific inhibitor of JNK, protects dopaminergic neurous both from MPP+-induced neuronal apoptosis in vitroand in MPTP Parkinson's disease model. These results support JNK inhibition as a potential strategy in treating Parkinson's disease.
-
140浏览
-
0点赞
-
0收藏
-
0分享
-
751下载
-
0
-
引用